Medindia

X

OncoGenex To Present At The BioContact Quebec 2008 Annual Conference

Wednesday, October 1, 2008 General News J E 4
Advertisement
BOTHELL, WA and VANCOUVER, Oct. 1 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc (NASDAQ: OGXI) will present at the BioContact Quebec 2008 annual partnering symposium on October 2 at 4:30 pm ET in the Salle Laval at the Chateau Frontenac in Quebec City. OncoGenex' President and Chief Executive Officer, Scott Cormack, will provide a corporate overview at the conference, including a discussion of the Company's lead cancer drug candidate OGX-011 nearing completion of multiple Phase 2 clinical trials.



About OncoGenex Pharmaceuticals



OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.



SOURCE OncoGenex Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Advanced Life Sciences Announces NDA Submission fo...
S
Nordic Omega-3 Gummies From Nordic Naturals - Plea...